List of Excipients in Branded Drug JEMPERLI

« Back to Dashboard

JEMPERLI Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

JEMPERLI, the branded dostarlimab-gxly antibody from GSK, uses a conventional liquid intravenous formulation built around histidine buffering, sucrose stabilization, and polysorbate 80 control of interfacial stress. The formulation is commercially important because it supports a ready-to-dilute, single-dose presentation without lyophilization or reconstitution.

The main commercial opportunity is not a differentiated excipient platform. It is expansion of JEMPERLI’s use across mismatch-repair-deficient and microsatellite-instability-high solid tumors, combined with manufacturing scale, supply reliability, and potential lifecycle work on ready-to-use or subcutaneous presentations.

What is JEMPERLI and how is it administered?

JEMPERLI is dostarlimab-gxly, a humanized programmed death receptor-1, or PD-1, blocking antibody. It is administered by intravenous infusion after dilution in 0.9% sodium chloride or 5% dextrose injection.[1]

The U.S. product is supplied as a sterile, preservative-free solution:

Attribute	JEMPERLI specification
Active ingredient	Dostarlimab-gxly
Dosage form	Intravenous solution
Strength	500 mg/10 mL
Concentration	50 mg/mL
Container	Single-dose vial
Route	Intravenous infusion
Key indications	dMMR advanced or recurrent endometrial cancer; first-line treatment with carboplatin and paclitaxel for primary advanced or recurrent dMMR endometrial cancer
Diluent	0.9% sodium chloride or 5% dextrose
Storage	Refrigerated at 2°C to 8°C; do not freeze; protect from light
U.S. regulatory category	Biologic licensed under a BLA

JEMPERLI received accelerated FDA approval in April 2021 for adult patients with recurrent or advanced dMMR endometrial cancer that had progressed on or after prior platinum-containing therapy.[2] The FDA converted the indication to regular approval in February 2023 after confirmatory data supported clinical benefit.[3] In August 2024, the FDA approved JEMPERLI with carboplatin and paclitaxel, followed by JEMPERLI monotherapy, for primary advanced or recurrent dMMR endometrial cancer.[4]

What excipients are used in JEMPERLI?

JEMPERLI uses a short excipient list:

Excipient	Functional role
L-histidine	Primary buffer component
L-histidine hydrochloride monohydrate	Conjugate buffer component and pH control
Sucrose	Tonicity adjustment and protein stabilization
Polysorbate 80	Surfactant that limits adsorption and aggregation
Water for injection	Vehicle

The U.S. prescribing information identifies histidine, histidine hydrochloride monohydrate, sucrose, polysorbate 80, and water for injection as inactive ingredients.[1]

The formulation strategy is consistent with common monoclonal-antibody development practice. Histidine systems provide buffering near mildly acidic pH values used for many antibodies. Sucrose helps reduce conformational damage during storage and handling. Polysorbate 80 reduces protein adsorption to vial, syringe, tubing, and infusion-bag surfaces.

How does the JEMPERLI formulation create commercial value?

The formulation creates value through manufacturability and administration simplicity rather than through novel excipient chemistry.

Ready-to-dilute intravenous presentation

JEMPERLI is supplied as a concentrated liquid that is diluted before infusion. This eliminates the reconstitution step required for lyophilized antibodies. Hospitals avoid sterile-water reconstitution, extended preparation time, and an additional manipulation step that can create dosing and contamination risks.

High-concentration liquid formulation

At 50 mg/mL, the product can deliver a substantial antibody dose from a relatively small vial volume. The concentration supports the 500 mg dose used in the approved dosing schedule and reduces shipping and storage volume relative to lower-concentration presentations.

Conventional excipient profile

The use of sucrose, histidine, and polysorbate 80 can simplify analytical development and raw-material qualification because these materials are widely used in biologics manufacturing. The tradeoff is that the formulation has less intrinsic differentiation from competing PD-1 antibodies.

Cold-chain compatibility

The product requires refrigerated storage. This creates a predictable biologics supply chain but leaves room for commercial improvement through enhanced temperature stability, lower shipping cost, or reduced excursion risk.

What formulation patents may protect JEMPERLI?

JEMPERLI is a therapeutic biologic, not a conventional small-molecule drug. Its principal U.S. regulatory protection is therefore associated with the Biologics Price Competition and Innovation Act framework and the FDA Purple Book, not the small-molecule Orange Book.[5]

Potential protection categories include:

1. Antibody composition claims covering dostarlimab or related anti-PD-1 antibodies.
2. Complementarity-determining region and variable-region sequence claims.
3. Antibody production-cell and manufacturing claims.
4. Formulation claims covering concentration, pH, buffer, sugar, surfactant, and stability conditions.
5. Therapeutic method claims covering dMMR or MSI-H tumors.
6. Combination-treatment claims involving platinum chemotherapy and taxane therapy.
7. Biomarker-selection claims covering patients with mismatch-repair deficiency.

The practical strength of the formulation estate depends on claim scope and validity. A narrow claim covering histidine, sucrose, and polysorbate 80 at specific concentrations may be vulnerable to design-around using alternative buffers, sugars, or surfactants. Broader claims tied to stability performance, aggregation control, or a defined antibody concentration may create stronger barriers if supported by comparative data.

The FDA label identifies JEMPERLI as a biologic and does not provide an Orange Book-style list of formulation patents.[1] Commercial teams should therefore distinguish between patent protection, FDA reference-product exclusivity, and regulatory protections linked to the licensed biologic.

When does JEMPERLI lose U.S. biologic exclusivity?

JEMPERLI’s reference-product exclusivity began with its first U.S. licensure in April 2021. Under U.S. law, a biosimilar application generally cannot be approved until 12 years after the reference product’s first licensure, subject to statutory limitations and patent litigation.[6]

Protection	Approximate date or period
First U.S. approval	April 2021
Four-year biosimilar application submission bar	April 2025
Twelve-year reference-product exclusivity	April 2033
Patent and regulatory launch analysis	Must be assessed separately from biologic exclusivity

The 12-year period does not guarantee market exclusivity through 2033 in every jurisdiction, and it does not eliminate the effect of patent settlements, pediatric exclusivity, injunctions, or other regulatory provisions. It does establish the central U.S. timing framework for biosimilar competition.

JEMPERLI is not a small-molecule product with conventional generic substitution. A competing product would generally require biosimilar approval or a separate biologic license.

What is the Orange Book and Purple Book status of JEMPERLI?

JEMPERLI is not evaluated through the standard Orange Book patent-certification pathway used for small-molecule abbreviated new drug applications. It is listed as a biological product in FDA’s Purple Book framework.

This distinction affects competitive timing:

Issue	Small-molecule drug	JEMPERLI
Primary abbreviated pathway	ANDA	Biosimilar application under section 351(k)
Patent certification	Paragraph I-IV framework	Patent-exchange and litigation process under BPCIA
FDA reference	Orange Book	Purple Book
Competition type	Generic	Biosimilar or interchangeable biosimilar
Substitution	Often automatic if therapeutically equivalent	Depends on interchangeability designation and state law
Formulation design-around	Common generic strategy	Possible, but subject to biosimilarity and manufacturing requirements

A Paragraph IV challenge is therefore not the normal legal mechanism for attacking JEMPERLI. Biosimilar applicants may challenge patents through the BPCIA patent dance and related federal litigation.

What biosimilar risks exist for JEMPERLI?

The earliest structural U.S. biosimilar competition date is tied to the 12-year reference-product exclusivity period, placing the main U.S. risk around 2033. Actual launch timing could occur later because of patents, settlement agreements, manufacturing readiness, regulatory review, or commercial decisions.

The largest biosimilar barriers are likely to be:

• Complex analytical similarity requirements for a PD-1 antibody.
• Need to establish similarity across multiple quality attributes.
• Clinical and pharmacology requirements determined by FDA.
• Manufacturing-site qualification and process validation.
• Global regulatory divergence.
• Lower expected return than for high-volume autoimmune antibodies.
• Indication-specific pricing pressure in oncology.

The risk is moderated by JEMPERLI’s narrower current market relative to leading PD-1 products such as pembrolizumab and nivolumab. A biosimilar developer would need sufficient demand across approved indications and geographies to justify development and manufacturing investment.

What excipient lifecycle opportunities exist for JEMPERLI?

Subcutaneous delivery

The strongest formulation opportunity is a subcutaneous version. A subcutaneous product could reduce infusion-center time, lower administration costs, and support outpatient or home-based treatment where clinically appropriate.

Subcutaneous development would likely require:

• Higher antibody concentration.
• Evaluation of viscosity and injectability.
• Assessment of injection-site tolerability.
• Possible use of a delivery device.
• New container-closure and extractables studies.
• Human-factor validation for prefilled syringe or autoinjector use.

At 50 mg/mL, the current intravenous concentration may not be sufficient for a practical subcutaneous dose if the required volume is high. A high-concentration formulation may require different stabilizer and surfactant levels.

Ready-to-use infusion bags

A pharmacy-ready bag or premixed presentation could reduce preparation steps. The commercial benefit would depend on chemical and physical stability after dilution, compatibility with common infusion materials, and whether the product can maintain quality during refrigerated storage and controlled room-temperature handling.

Improved temperature stability

An extended room-temperature excursion allowance would reduce wastage and simplify hospital inventory management. This opportunity requires strong data on aggregation, fragmentation, potency, particles, and container compatibility.

Alternative surfactants

Polysorbate 80 can undergo oxidation and hydrolysis, with potential effects on protein stability and subvisible particle formation. Alternative surfactants, including polysorbate 20 or newer low-peroxide surfactant systems, could be evaluated. Any replacement would require a full comparability package and would not automatically create a commercially meaningful advantage.

Lyophilized presentation

Lyophilization could improve long-term stability but would reintroduce reconstitution complexity, increase manufacturing cost, and reduce the current ready-to-dilute advantage. It is therefore a weaker commercial opportunity unless liquid stability proves limiting.

How does JEMPERLI compare with competing PD-1 drugs?

Product	Sponsor	Active ingredient	Typical formulation strategy	Commercial position
JEMPERLI	GSK	Dostarlimab-gxly	Liquid IV antibody with histidine, sucrose, and polysorbate 80	Biomarker-selected endometrial cancer and other dMMR/MSI-H opportunities
Keytruda	Merck	Pembrolizumab	Liquid IV formulation; broad oncology label	Dominant PD-1 franchise with extensive indication breadth
Opdivo	Bristol Myers Squibb	Nivolumab	Liquid IV formulation; broad oncology label	Large multi-tumor immuno-oncology franchise
Libtayo	Regeneron/Sanofi	Cemiplimab-rwlc	Liquid IV formulation	Selected solid-tumor indications
Imfinzi	AstraZeneca	Durvalumab	Liquid IV formulation	PD-L1 product with broad oncology use

JEMPERLI’s formulation is commercially credible but not strongly differentiated from competing checkpoint inhibitors. Its differentiation rests on clinical evidence, biomarker targeting, treatment combinations, physician adoption, and expansion into additional dMMR/MSI-H tumors.

What is the commercial opportunity for JEMPERLI?

The commercial opportunity is concentrated in three areas.

Endometrial cancer expansion

The 2024 first-line approval with carboplatin and paclitaxel materially expanded the addressable treatment setting. Combination use increases the number of eligible patients and moves JEMPERLI earlier in the treatment sequence.[4]

Tumor-agnostic biomarker use

dMMR and MSI-H biology occurs across multiple tumor types. A successful tumor-agnostic strategy could expand demand beyond endometrial cancer, although competition from pembrolizumab is substantial.

Combination therapy

JEMPERLI’s approval with chemotherapy creates a platform for future studies with other antineoplastic agents. Combination development may support additional patent claims and extend commercial relevance, but it also increases clinical-development cost and safety-management complexity.

GSK reported JEMPERLI sales of approximately £248 million in 2023 and approximately £383 million in 2024, reflecting growth after the first-line endometrial-cancer expansion.[7,8] The product remains smaller than the leading PD-1 franchises, leaving meaningful upside if GSK expands indications and maintains biomarker leadership.

Which companies are challenging JEMPERLI?

Publicly visible commercial competition comes primarily from established checkpoint inhibitors rather than from generic manufacturers.

The principal competitive products are:

• Merck’s Keytruda, pembrolizumab.
• Bristol Myers Squibb’s Opdivo, nivolumab.
• Regeneron and Sanofi’s Libtayo, cemiplimab.
• AstraZeneca’s Imfinzi, durvalumab.
• Other immunotherapy combinations used in advanced and recurrent endometrial cancer.

A direct biosimilar challenge is more likely to emerge after the U.S. reference-product exclusivity period and after relevant patent disputes or settlements are resolved. As of the regulatory milestones cited here, the material commercial threat is branded competition and clinical differentiation, not an established near-term biosimilar launch.

How strong is the JEMPERLI formulation strategy?

The formulation is operationally strong and strategically moderate.

Strengths

• Simple excipient system.
• Ready-to-dilute liquid presentation.
• High concentration for a 500 mg dose.
• Familiar raw materials.
• Compatibility with standard hospital infusion practice.
• No need for reconstitution before dilution.

Limitations

• Requires refrigerated storage.
• Uses a conventional excipient combination that may be difficult to protect broadly.
• Intravenous infusion creates administration burden.
• Polysorbate-related degradation and particle risks require control.
• No evident formulation feature creates a major barrier to competing antibody development.

The strongest defensible intellectual-property position is likely to come from the antibody, manufacturing process, biomarker-selected methods of treatment, and combination regimens. Excipient claims can add incremental protection but are unlikely to carry the commercial estate alone.

What generic launch risks exist for JEMPERLI?

A traditional generic launch is not the relevant scenario. The principal scenarios are:

Scenario	Timing	Commercial effect
No biosimilar before exclusivity expiry	Before approximately 2033	GSK retains reference-product position
First biosimilar after exclusivity expiry	Around or after 2033	Price pressure and hospital formulary competition
Patent settlement	Variable	Entry date may be earlier than full patent expiry
Subcutaneous lifecycle product	Before biosimilar entry	Potentially protects administration convenience and patient retention
New indication expansion	Before or after biosimilar entry	Increases market size but may not block biosimilar use
Formulation redesign	Variable	May reduce administration cost or improve supply resilience

Key Takeaways

• JEMPERLI is a 50 mg/mL intravenous dostarlimab solution supplied in a 500 mg/10 mL single-dose vial.
• Its core excipients are histidine, histidine hydrochloride monohydrate, sucrose, polysorbate 80, and water for injection.
• The formulation prioritizes liquid stability, high concentration, and hospital preparation simplicity.
• JEMPERLI is a biologic listed through the Purple Book framework, not a conventional Orange Book small-molecule product.
• U.S. reference-product exclusivity began in 2021 and generally extends for 12 years, placing the key biosimilar window around 2033.
• The strongest lifecycle opportunity is a subcutaneous or otherwise lower-burden administration format.
• Formulation patents may support the estate, but antibody, manufacturing, biomarker, and combination claims are likely to have greater commercial importance.
• GSK’s 2024 first-line endometrial-cancer approval expanded the product’s market opportunity.
• Keytruda and Opdivo remain the major commercial competitors.
• The main near-term threat is branded checkpoint-inhibitor competition, not a conventional generic.

FAQs About JEMPERLI Excipients and Commercial Strategy

Is JEMPERLI preservative-free?

Yes. JEMPERLI is supplied as a sterile, preservative-free single-dose vial.[1]

Can JEMPERLI be administered by subcutaneous injection?

The marketed U.S. product is administered by intravenous infusion. A subcutaneous presentation would require a separate formulation, delivery system, and regulatory approval.

Does JEMPERLI contain polysorbate 80?

Yes. Polysorbate 80 is included as a surfactant to help control protein adsorption and aggregation.[1]

Is JEMPERLI interchangeable with Keytruda?

No. JEMPERLI and Keytruda are different biologic products with different active antibodies, labels, clinical data, and regulatory status.

Will a JEMPERLI biosimilar be substitutable automatically?

Not necessarily. Automatic substitution depends on FDA interchangeability status and applicable state pharmacy laws. Biosimilar approval alone does not establish automatic substitution in every setting.

References

1. U.S. Food and Drug Administration. (2024). JEMPERLI (dostarlimab-gxly) injection, prescribing information.
2. U.S. Food and Drug Administration. (2021, April 22). FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced or recurrent endometrial cancer.
3. U.S. Food and Drug Administration. (2023, February 9). FDA converts accelerated approval to regular approval for dostarlimab-gxly for endometrial cancer.
4. U.S. Food and Drug Administration. (2024, August 1). FDA approves dostarlimab-gxly with chemotherapy for primary advanced or recurrent endometrial cancer.
5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
6. Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.
7. GSK plc. (2024). Annual report 2023.
8. GSK plc. (2025). Annual report 2024.